Table 3.
Clinical parameters at baseline in (a) type 1 and (b) 2 diabetes patients
| N | M ± SD | LQ/UQ | Med | |
|---|---|---|---|---|
| Panel a | ||||
| Age (years) | 240 | 36.0 ± 11.8 | 26.3/45.4 | 34.0 |
| Body mass index (kg/m2) | 240 | 24.8 ± 4.1 | 22.0/26.6 | 24.0 |
| Waist circumference (cm) | 239 | 86.1 ± 12.6 | 76.2/94.0 | 85.0 |
| Hemoglobin A1c (%) | 237 | 6.5 ± 1.2 | 5.8/6.9 | 6.3 |
| Glucose (mg/dl) | 232 | 133.4 ± 48.0 | 106.0/150.5 | 121.0 |
| Total cholesterol (mg/dl) | 238 | 184.9 ± 38.6 | 160.5/207.5 | 180.5 |
| HDL cholesterol (mg/dl) | 236 | 60.5 ± 17.3 | 48.5/70.5 | 59 |
| LDL cholesterol (mg/dl) | 236 | 108.9 ± 33.5 | 87.0/126.5 | 105.0 |
| Triglycerides (mg/dl) | 238 | 89.6 ± 58.2 | 56.0/102.0 | 74.0 |
| ASAT (U/l) | 238 | 22.4 ± 8.5 | 17.0/25.0 | 20.2 |
| ALAT (U/l) | 238 | 25.2 ± 18.5 | 15.9/28.0 | 20.9 |
| GGT (U/l) | 238 | 22.1 ± 21.7 | 11.1/26.0 | 16.0 |
| hsCRP (mg/dl) | 237 | 0.2 ± 0.3 | 0.1/0.2 | 0.1 |
| C-peptide (ng/ml) | 236 | 1.2 ± 0.9± | 0.5/1.4/ | 1.0 |
| SBP (mmHg) | 237 | 129.5 ± 14.9 | 120.5/138.0 | 129.0 |
| DBP (mmHg) | 237 | 78.0 ± 9.8 | 71.0/84.0 | 77.0 |
| VO2max (ml min.−1 kg−1) | 203 | 27.0 ± 7.8 | 22.1/31.3 | 25.7 |
| FMD (%) | 201 | 6.8 ± 6.6 | 2.2/10.6 | 5.6 |
| NMD (%) | 196 | 16.4 ± 9.5 | 9.3/22.1 | 15.8 |
| Panel b | ||||
| Age (years) | 458 | 53.5 ± 10.4 | 47.1/62.4 | 54.8 |
| Body mass index (kg/m2) | 456 | 31.7 ± 6.0 | 27.1/35.4 | 31.1 |
| Waist circumference (cm) | 455 | 105.9 ± 14.7 | 95.0/115.5 | 105.5 |
| Hemoglobin A1c (%) | 452 | 6.4 ± 0.8 | 5.8/6.8 | 6.2 |
| Fasting glucose (mg/dl) | 438 | 125.0 ± 28.6 | 107.0/137.0 | 122.0 |
| Total cholesterol (mg/dl) | 451 | 206.2 ± 42.0 | 180.0/234.0 | 203.0 |
| HDL cholesterol (mg/dl) | 448 | 46.4 ± 12.8 | 37.0/53.0 | 45.0 |
| LDL cholesterol (mg/dl) | 448 | 130.5 ± 36.1 | 105.2/153.5 | 129.0 |
| Triglycerides (mg/dl) | 451 | 176.0 ± 165.2 | 98.0/203.8 | 137.0 |
| ASAT (U/l) | 451 | 25.4 ± 11.0 | 19.0/29.0 | 23.0 |
| ALAT (U/l) | 451 | 34.5 ± 19.5 | 21.9/41.8 | 29.0 |
| GGT (U/l) | 451 | 43.0 ± 51.0 | 21.4/48.0 | 31.6 |
| hsCRP (mg/dl) | 446 | 0.4 ± 0.7 | 0.1/0.5 | 0.3 |
| C-peptide (ng/ml) | 445 | 3.3 ± 1.6 | 2.2/4.2 | 3.0 |
| SBP (mmHg) | 447 | 141.6 ± 17.1 | 129.5/152.0 | 141.5 |
| DBP (mmHg) | 447 | 85.1 ± 10.5 | 78.0/91.5 | 84.5 |
| VO2max (ml min.−1 kg−1) | 317 | 19.1 ± 4.9 | 15.6/21.8 | 18.7 |
| FMD (%) | 332 | 5.6 ± 5.3 | 1.9/8.25 | 4.5 |
| NMD (%) | 338 | 12.2 ± 7.3 | 6.6/16.2 | 11.5 |
Number (N) of type 1 (DM) participants or samples, M mean, SD standard deviation, Med median, LQ lower quartile, UQ upper quartile, HDL high-density lipoprotein, LDL low-density lipoprotein, ASAT Aspartate-Aminotransferase, ALAT Alanine-Aminotransferase, GGT Gamma-Glutamyltransferase, hsCRP high sensitive C-reactive protein, SBP systolic blood pressure, DBP diastolic blood pressure. VO 2 max maximal oxygen uptake, FMD flow-mediated (endothelium-dependent) vasodilatation, NMD nitrogen-mediated (endothelium independent) vasodilatation